Desvenlafaxine Tablet, Film Coated, Extended Release
Product Images NDC 60687-607

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Desvenlafaxine (NDC 60687-607). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by American Health Packaging, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Ahp60721

Ahp60721
FDA Label Image

50 mg Desvenlafaxine Extended-release Tablet Blister (Blister)

50 mg Desvenlafaxine Extended-release Tablet Blister (Blister)
FDA Label Image

50 mg Desvenlafaxine Extended-release Tablets Carton (Carton)

50 mg Desvenlafaxine Extended-release Tablets Carton (Carton)
Desvenlafaxine Extended-Release Tablets, NDC 60687-607-21, come in a package of 30 tablets (3 x 10) for Rx use. Each tablet contains 76 mg desvenlafaxine succinate equivalent to 50 mg sty. It is recommended to swallow tablets whole and to dispense with the accompanying Medication Guide to each patient. The usual dosage information can be found in the packaging. Store at 20°C - 25°C (68°F -77°F) and keep out of reach of children. The drug product contained in this package is from NDC # 50540400, West Ward Pharmaceuticals Core, and it is distributed by American Health Packaging 760721 in Columbus, Ohio.*
FDA Label Image

Figure 1: Impact Of Intrinsic Factors (renal, Hepatic Impairment And Population Description) On Desvenlafaxine Pharmacokinetics (Figure 1)

Figure 1: Impact Of Intrinsic Factors (renal, Hepatic Impairment And Population Description) On Desvenlafaxine Pharmacokinetics (Figure 1)
FDA Label Image

Figure 2: Effect Of Other Drugs On Desvenlafaxine Pharmacokinetics (Figure 2)

Figure 2: Effect Of Other Drugs On Desvenlafaxine Pharmacokinetics (Figure 2)
This appears to be a statistical analysis output related to the effect of Ketoconazole on the pharmacokinetics of a drug via CYP3A4 inhibition. It includes information on the geometric mean ratio and confidence intervals for changes observed in Cmax, AUC, and T. However, without further context or information it is difficult to provide a specific description or interpretation.*
FDA Label Image

Figure 3: Effects Of Desvenlafaxine On Pharmacokinetics Of Other Drugs (Figure 3)

Figure 3: Effects Of Desvenlafaxine On Pharmacokinetics Of Other Drugs (Figure 3)
FDA Label Image

Figure 4: Estimated Proportion Of Relapses Vs. Number Of Days Since Randomization (study 5) (Figure 4)

Figure 4: Estimated Proportion Of Relapses Vs. Number Of Days Since Randomization (study 5) (Figure 4)
The text seems to be a chart displaying estimates of the proportion of patients experiencing relapse. There are four values presented, 50%, 4%, 30%, and 20%. The rest of the text appears to be axis labels and is not applicable to the description.*
FDA Label Image

Figure 5: Estimated Proportion Of Relapses Vs. Number Of Days Since Randomization (study 6) (Figure 5)

Figure 5: Estimated Proportion Of Relapses Vs. Number Of Days Since Randomization (study 6) (Figure 5)
The text describes a graph showing the estimated proportion of patients experiencing relapse over time (in days) following randomization. It compares two treatments, Desvenlafaxine and Placebo. The y-axis is not labeled with specific values but appears to show a range from 0% to 200%.*
FDA Label Image

Structural Formula (Structure)

Structural Formula (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.